OhioHealth Partners with bioMérieux as Newest Global Antimicrobial Stewardship Center of Excellence
MWN-AI** Summary
OhioHealth, a not-for-profit healthcare system based in Columbus, Ohio, has been designated as the newest Antimicrobial Stewardship (AMS) Center of Excellence by bioMérieux, a global leader in in vitro diagnostics. This recognition makes OhioHealth the fourth healthcare system in the United States and the first regional system to receive this prestigious title. The partnership is part of a global initiative aimed at combating antimicrobial resistance (AMR), a significant public health challenge that is projected to surpass cancer as a leading cause of death by 2050.
The collaboration emphasizes the integral role of laboratory diagnostics in advancing patient care and managing infectious diseases. Through OhioHealth’s Microbiology Laboratory, this partnership will leverage innovative technologies to promote appropriate antibiotic use, thereby reducing unnecessary prescriptions and improving patient outcomes. OhioHealth serves over 50 out of the 88 counties in Ohio, reflecting a strong regional commitment to enhancing patient safety and care standards.
Andrea K. Smith, OhioHealth's Senior Director of Laboratory Services, expressed that this recognition validates their ongoing efforts in patient-centered care. The partnership will also involve bioMérieux providing training, automated lab services, and quality management support to enhance OhioHealth’s AMS initiatives.
The AMS Centers of Excellence program, initiated by bioMérieux in 2021, aims to raise awareness about AMR and the critical impact that rapid diagnostics can have in promoting effective antibiotic stewardship. As the program expands globally, OhioHealth joins a network of leading healthcare institutions dedicated to innovative and collaborative healthcare solutions.
Overall, this collaboration stands as a testament to OhioHealth's mission of providing exceptional healthcare while actively contributing to the global fight against antimicrobial resistance.
MWN-AI** Analysis
The recent partnership between OhioHealth and bioMérieux to establish the latter as the newest Antimicrobial Stewardship (AMS) Center of Excellence is a significant event in the healthcare sector, particularly in the fight against antimicrobial resistance (AMR). This collaboration places OhioHealth in a select group of institutions committed to addressing a critical global health challenge, which is expected to enhance its reputation and operational effectiveness within the healthcare landscape.
### Market Analysis
For investors and stakeholders, this partnership signals OhioHealth's strengthening position as a leader in healthcare innovation and patient safety. By integrating advanced diagnostic technologies and embracing a stewardship model, OhioHealth is likely to reduce costs associated with inappropriate antibiotic use and improve patient outcomes, which is beneficial for both its financial performance and reputation.
### Strategic Implications
The recognition as an AMS Center of Excellence not only boosts OhioHealth’s brand equity but also opens the door for potential funding opportunities and partnerships aimed at further enhancing their infectious disease management capabilities. As the healthcare sector increasingly aligns with value-based care principles, OhioHealth's proactive stance on AMR places it ahead of competitors, making it an attractive investment option.
### Economic Forecast
Given that AMR is projected to become a leading cause of mortality globally, investments in effective antimicrobial diagnostics are essential. OhioHealth’s strategic alignment with bioMérieux may yield long-term financial benefits through reduced healthcare costs via decreased hospital stays and readmissions.
### Conclusion
For investors, monitoring OhioHealth's initiatives and outcomes from this partnership is crucial, positioned against the backdrop of rising AMR concerns. This endeavor places OhioHealth at the forefront of public health efforts, which could further enhance its financial stability and growth potential in an increasingly competitive market. As such, OhioHealth presents a compelling prospect for investment in the evolving healthcare ecosystem.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
OhioHealth is only the 4 th to receive the designation in the country, and the first regional healthcare system.
SALT LAKE CITY and COLUMBUS, Ohio , Aug. 26, 2025 /PRNewswire/ -- bioMérieux , a world leader in in vitro diagnostics, is proud to announce Columbus, Ohio , based, not-for-profit healthcare system, OhioHealth and The OhioHealth Microbiology Laboratory is the nation's newest Antimicrobial Stewardship (AMS) Center of Excellence.
The bioMérieux AMS Center of Excellence initiative represents a unique set of health systems worldwide that share the same commitment as bioMérieux – to improve AMS and slow the spread of antimicrobial resistance (AMR), a growing global public health threat. This partnership recognizes the critical role of the laboratory in driving data-informed diagnostic practices to enhance patient care, advance infectious disease management, and accelerate the fight against AMR. OhioHealth is the first regional healthcare system in the AMS Center of Excellence network, covering more than 50 of the 88 counties in the state of Ohio .
This partnership illustrates OhioHealth's commitment to setting the national standard on patient safety and positive outcomes. Leaning into its core values of excellence and stewardship, this collaboration supports the overall mission to improve the health of those OhioHealth serves through exceptional healthcare for all.
" OhioHealth is a national leader, providing exceptional, high-quality care for each patient we have the honor of serving," said Andrea K. Smith , M.S., MB(ASCP) CM OhioHealth Senior Director, Laboratory Services. " For our system microbiology laboratory to be recognized as an Antimicrobial Stewardship (AMS) Center of Excellence by bioMérieux, it serves as validation for what we have passionately worked to achieve. We always put patients at the center of everything we do. By utilizing innovative technologies and best practices, we will continue to lead, ensuring our patients have the best possible outcomes. "
No one is safe from AMR. By 2050, AMR is predicted to surpass cancer as the leading cause of death globally. 1 Early and accurate diagnostic testing, the mission of the OhioHealth Microbiology Laboratory, plays a pivotal role in guiding appropriate antibiotic use, reducing unnecessary prescriptions, and improving patient outcomes. Economically, diagnostics can reduce healthcare costs by minimizing the use of broad-spectrum antibiotics and, most importantly, decreasing hospital stays and readmissions.
"Diagnostics are among the most powerful tools we have in the fight against AMR," said Jennifer Zinn , bioMérieux Executive Vice President of Clinical Operations. "Advancing AMS requires collaboration across the entire healthcare ecosystem—from clinicians, lab professionals, pharmacists, and beyond. We're honored to welcome OhioHealth to this global movement of forward-thinking health systems. By leveraging our collective expertise and embracing diagnostics-driven stewardship, we can accelerate meaningful change, harness innovation, and ultimately help improve patient outcomes."
Through the partnership, bioMérieux will provide its expertise in advanced diagnostic technologies, IT and lab automation, as well as training and quality management support. A dedicated bioMérieux Center of Excellence team will support OhioHealth with its unique AMS initiatives to optimize these high-value solutions to improve patient care and mitigate the spread of AMR.
ABOUT GLOBAL ANTIMICROBIAL STEWARDSHIP AND AMS CENTERS OF EXCELLENCE
In 2021, bioMérieux established the Antimicrobial Stewardship Centers of Excellence program to bring attention to the threat of antimicrobial resistance and to accelerate the impact that infectious diseases diagnostics have in facilitating antimicrobial stewardship and better patient care. OhioHealth is the fourth U.S. AMS Center of Excellence. In addition to OhioHealth, bioMérieux collaborates with 15 other leading hospitals across 13 countries to integrate innovative diagnostic solutions into AMS programs globally.
According to a landmark study published in The Lancet in 2022, as of 2019, an estimated 4.95 million annual deaths were associated with bacterial AMR, with 1.27 million deaths directly attributable to it. 2 In the U.S., the impact of AMR is significant. According to the Centers for Disease Control and Prevention (CDC), at least 2.8 million people in the U.S. acquire antibiotic-resistant infections each year, and more than 35,000 people die as a result. 3
To learn more about the AMS Centers of Excellence program, visit www.biomerieux.com/corp/en/our-offer/strategic-partnerships/ams-centers-of-excellence.html .
References:
- O'Neill, Jim, Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance. London, UK ., 2016 May
- Murray, Christopher J L et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb.
- Amin VP, Dhanani M, Patel J, Dhawan A, Mahesh G, Chenna VSH, Kyada S, Dekhne A, Desai HD. 2233. Burden of Bacterial Antimicrobial Resistance in United States in 2019: A Systematic Analysis. Open Forum Infect Dis. 2023 Nov 27;10(Suppl 2): ofad500.1855.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4.0 billion, with over 93% of sales outside of France . bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com
ABOUT OHIOHEALTH
Based in Columbus, Ohio , OhioHealth is a nationally recognized, not-for-profit, charitable, healthcare outreach of the United Methodist Church.
Serving its communities since 1891, OhioHealth is a family of 35,000 associates, physicians and volunteers, and a network of 16 hospitals, three joint-venture hospitals, 200+ ambulatory sites and other health services spanning a 50-county area. It has been recognized by FORTUNE as one of the "100 Best Companies to Work For" 15 times since 2007. For more information, visit ohiohealth.com .
SOURCE bioMérieux; OhioHealth
FAQ**
How will the collaboration between OhioHealth and bioMérieux, highlighted by the "bioMérieux ADR BMXXY," specifically enhance antimicrobial stewardship initiatives within Ohio's healthcare system?
What key outcomes does OhioHealth anticipate from being designated as a Center of Excellence by bioMérieux, and how does the "bioMérieux ADR BMXXY" play a role in achieving these goals?
In what ways will bioMérieux's advanced diagnostic technologies and IT support, referenced as "bioMérieux ADR BMXXY," contribute to reducing the economic impact of antimicrobial resistance in OhioHealth facilities?
How does OhioHealth plan to integrate the expertise from bioMérieux, especially relating to "bioMérieux ADR BMXXY," into its existing workflows to improve infectious disease management and patient outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about Biomerieux ADR (OTC: BMXXY).
NASDAQ: BMXXY
BMXXY Trading
12.13% G/L:
$12.11 Last:
10,804 Volume:
$10.80 Open:
